• Adults ≥ 18 years of age

• Patients undergoing axillary lymph node dissection with or without lymphatic reconstruction at diagnosis

• Patients must have ICG lymphatic mapping performed prior to axillary lymph node dissection

• A clinical diagnosis consistent with stage Tis-T4N0-3M0 breast cancer.

• ECOG Performance Status of 0-1

• Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician and approved by the PI\] may be included).

• Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.

• Subjects of childbearing potential (SOCBP) must have a negative pregnancy test prior to enrollment and be using an adequate method of contraception to avoid pregnancy throughout study participation to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.

• Patients must undergo a baseline physical therapy evaluation prior to axillary lymph node dissection.

• Patients who have received neoadjuvant chemotherapy are required to see physical therapy for lymphedema assessment following completion of chemotherapy prior to surgery.